EU Rejects Cymbalta For Fibromyalgia Treatment

Law360, New York (October 24, 2008, 12:00 AM EDT) -- In a blow to Eli Lilly & Co., the European Union's drug-regulating body has recommended against allowing the pharmaceutical giant to market Cymbalta as a fibromyalgia treatment after finding that the benefits of the drug – which is already approved in Europe for depression and anxiety – in the treatment of the disease do not outweigh its risks.

The European Medicines Agency's Committee for Medicinal Products for Human Use said Thursday it had adopted a negative opinion recommending the refusal of a change to the marketing...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.